MedPath

Prospective Post-market Study Examining the Effectiveness of the EcoFit®

Not yet recruiting
Conditions
Degenerative Joint Disease
Osteoarthritis, Hip
Femoral Fracture
Traumatic Arthritis
Interventions
Device: EcoFit® Total Hip System with implacross® E Polyethylene
Registration Number
NCT04918680
Lead Sponsor
Implantcast North America, LLC
Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of the EcoFit Hip with implacross E polyethylene for total hip replacement surgery.

Detailed Description

This study will assess the performance and success rate of the EcoFit Total Hip System. Survivorship and clinical outcomes will help determine implant success 36 months as defined by specific scoring systems and compared to other published data.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Subject must be a candidate for a total primary hip replacement.
  • Subject must have degenerative joint disease, including osteoarthritis or traumatic arthritis, OR a femoral fracture which can be treated by a primary hip replacement and no other hardware
  • Subject has a BMI of 40.00 kg/m2 or less at the time of enrollment
  • Subject is likely to be available for evaluation for the duration of the study
  • Subject is able and willing to sign the informed consent and follow study procedures
  • Subject is not pregnant
Exclusion Criteria
  • Subject has had a prior hip replacement in the subject hip
  • Subject has an active cancer or is a survivor for <5 years except for squamous cell or basal cell skin cancer
  • Subject has a chronic disease(s) where, in the opinion of the investigator, the disease will interfere with the patient's ability to follow the protocol
  • Subject is currently a documented substance abuser (alcohol or other addictions)
  • Subject has an infection, or history of infection (within the last 3 months), acute or chronic, local or systemic
  • Subject has a history of muscular, neurological or vascular deficiencies which compromise the affected extremity
  • Subject has a BMI > 40.00 kg/m2
  • Subject has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease)
  • Subject is a prisoner
  • Subject is pregnant
  • Subject has known materials sensitivity (to metals)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
EcoFit® Total Hip System with implacross® E PolyethyleneEcoFit® Total Hip System with implacross® E PolyethyleneSubjects who meet the indications for use for the EcoFit® Total Hip System with implacross® E Polyethylene and are candidates for a primary hip replacement.
Primary Outcome Measures
NameTimeMethod
Survival of the EcoFit Hip with implacross E polyethylene for total hip replacement surgery36 months

Evaluate the overall survivorship of the devices. Observed product-related complications and revisions are recorded and documented.

Secondary Outcome Measures
NameTimeMethod
Evaluate the pre to post-op change in the Harris Hip ScorePre-op, 6 months, 12 months, 24 months, 36 months

The Harris Hip Score tracks pain, function/gait, performance in functional activities, and range of motion as interpreted by the surgeon. The responses determine a score which can be compared in different intervals.

Evaluate the pre to post-op change in the WOMAC ScorePre-op, 6 months, 12 months, 24 months, 36 months

The Western Ontario McMaster Arthritis Index, a questionnaire completed by the patient, tracks pain, stiffness, and difficulty with daily activities.

Device related complicationsThrough completion of study, an average of 3.5 years

Detect any device related complications via the adverse events reporting

© Copyright 2025. All Rights Reserved by MedPath